Home > Journals > Minerva Pediatrica > Past Issues > Articles online first > Minerva Pediatrica 2017 Jun 22

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Cite this article as

 

 

Minerva Pediatrica 2017 Jun 22

DOI: 10.23736/S0026-4946.17.04938-6

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

The impact of valproic acid treatment on weight gain in pediatric patients with epilepsy

Pietro FERRARA 1, 2 , Antonio GATTO 1, Valeria BLASI 3, Federica DI RUSCIO 2, Domenica BATTAGLIA 4

1 Institute of Pediatrics, Catholic University Medical School, Rome, Italy; 2 Service of Pediatrics, Campus Bio-Medico University, Rome, Italy; 3 Food Sciences and Human Nutrition Unit, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy; 4 Infantile Neuropsychiatric Unit, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy


PDF


BACKGROUND: Valproic acid (VPA) is an antiepileptic drug, used for focal and generalized seizure. VPA treatment resulted in significant weight gain but there are no systematic data about the prevalence of this side effect. The aim of the study is to evaluate the weight gain of a paediatric population with epilepsy.
METHODS: We enrolled 38 patients, 17 female and 21 male with a mean age of 8.2±4.4 years. We evaluated data about height, weight and BMI at beginning of treatment and at 24, 36 and 48 months of follow-up.
RESULTS: There is a statistical significant difference between the percentile value of weight and BMI at baseline and at 36 and 48 months of follow-up (P value <0.01) but there isn’t statistical significant difference between the percentile value of height (P value 0.22 and 0.18).
CONCLUSIONS: We believe that a nutritional support should be guaranteed to the pediatric patients with epilepsy that begin the VPA therapy.


KEY WORDS: Epilepsy - Children - Antiepileptic drugs

top of page